Introduction
============

According to a United Nations report in 2015, the number of older people, those aged \>60 years, has markedly increased over the last few years worldwide.[@b1-ppa-12-1597] Globally, their number is expected to increase from 901 million to 1.4 billion between 2015 and 2030, representing a growth of about 56%.[@b1-ppa-12-1597] This increase tends to be higher in Asian countries; in Korea, the number is expected to grow by 77% during the same period.[@b1-ppa-12-1597]

Along with changes in lifestyle, developments in medical technology, and increase in life expectancy, the growth in the number of older people has caused increase in the incidence and prevalence of chronic diseases (CDs) such as heart disease, hypertension (HTN), diabetes mellitus (DM), COPD, and cancer.[@b2-ppa-12-1597] The increase in the prevalence of CDs has led to the long-term use of multiple medications, or polypharmacy. Hence, concerns about the effects of polypharmacy in patients with CDs have been raised.[@b3-ppa-12-1597] The rise in the number of medications used by each patient contributes to increase in drug combinations, which in turn, leads to elevated risk of adverse drug reactions (ADRs) and drug--drug interactions (DDIs).[@b3-ppa-12-1597],[@b4-ppa-12-1597] According to a study by Veehof et al, elderly patients prescribed with more medications tended to experience more ADRs than other patients, and the incidence rate of ADR increased proportionally with the increase in the number of medications administered long term.[@b5-ppa-12-1597]

Nowadays, a substantial number of symptomatic patients tend to use not only prescription medications but also nonprescription medications (ie, over-the-counter \[OTC\] medications), which can easily be obtained in pharmacies for the purpose of self-treatment.[@b6-ppa-12-1597],[@b7-ppa-12-1597] Older persons are the major consumers of OTC medications, consuming about 30% of OTC medications.[@b8-ppa-12-1597] However, OTC medications are not always safe and beneficial, and can expose the patients to unexpected health risks such as ADRs and DDIs.[@b9-ppa-12-1597],[@b10-ppa-12-1597] The incidence rates of ADRs and DDIs may be higher in patients who take both prescription and non-prescription medications. In addition, when there is no sufficient communication about the use of OTC medication between pharmacists and patients, it may lead to unintentional drug duplication (UDD) because pharmacists are poorly informed about the OTC medications that patients take. Patients under multiple medications may experience a higher frequency of UDD; therefore, it is necessary to continuously monitor the use of OTC medications and prescription medications.

Several studies on OTC medication use patterns and OTC drug-related problems (DRPs) have been conducted.[@b8-ppa-12-1597]--[@b14-ppa-12-1597] However, to our knowledge, studies regarding OTC drug use patterns in Korean adult patients who visit a community pharmacy are rare. The aims of this study were to 1) examine the use patterns of OTC medications and 2) assess patients' perceptions regarding the use of OTC medications in Korean patients with CDs who visited a community pharmacy.

Patients and methods
====================

Statement of ethics
-------------------

The institutional review board (IRB) of Chosun University reviewed and approved the proposed study (21041055-AB-N-01-2015-0043).

Study design
------------

This study consisted of conducting a self-reported survey on the patient's perception on OTC medication use and collecting the patient's medical record retrospectively from the pharmacy's database. To obtain data on the patient's perception toward the use of OTC medication, the self-reported survey was conducted. Before the initiation of the survey, the aims and procedure of the study had been explained to patients thoroughly, and written informed consents were acquired from all patients who agreed to participate in the survey. Participation was voluntary, and information provided from the participants was de-identified. The average time requested for the completion of each survey was \~10--15 minutes. Later, other necessary data of the survey participants were collected by reviewing their medical records from the pharmacy's database.

Study sites
-----------

To select an appropriate community pharmacy located in a small rural city where a number of elderly people (≥65 years old) live, we called 40 community pharmacies in Namwon in the North Jeolla Province of South Korea, explained the purposes of the study, and requested participation in it. However, only one middle-sized community pharmacy agreed to participate in the study. The composition of the patients visiting this community pharmacy showed various age groups because it was located in a newly developed area of Namwon. In 2015, \~85,000 people lived in Namwon, and among them, the elderly population accounted for about 24%. In particular, it is highly likely that most elderly people cannot receive health services in a timely manner because they live in rural areas where there are not enough hospitals and pharmacies to provide health services to them.

Study population
----------------

To recruit participants in the study site, a poster that included the study objectives and inclusion criteria was placed on a bulletin board at the pharmacy. Researchers asked almost all patients who visited the community pharmacy for a consultation between September 1, 2015, and September 30, 2015. Approximately 4,000 patients visited the study site during the study period. Questionnaires were distributed by the researchers to all patients who agreed to participate in the survey. The patients who met the following criteria were included in the study: patients aged ≥18 years and patients with CDs (defined as those who had continuously taken prescription medications due to the diseases for at least 3 months). Patients who were illiterate were excluded.

Data collection
---------------

A survey instrument was developed after reviewing published literature on OTC medication use. Prior to data collection, the contents of the survey instrument were reviewed by pharmacy researchers and experts, and a pilot test of the survey was conducted with 10 patients who were not considered as the study sample to ensure content validity and clarity. Minor revisions were made based on the results of the pilot test and feedback from the researchers and experts. Patients received questionnaires regarding OTC medications, which they had taken and the patients' perceptions on the use of OTC medications. A 5-point or 4-point Likert scale was used for responses to the questions about the perceptions. Patient demographic and clinical characteristics including gender, age, types of insurance, Korean standard classification of diseases, comorbidity and list of prescription drugs were retrospectively collected from the medical record by a trained community pharmacist.

Statistical methods
-------------------

Responses were coded, and all analyses were performed using SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA). Continuous variables were presented as mean ± SD, and categorical variables as frequency (n) and percentage (%). The independent *t*-test and chi-squared or Fisher's exact tests were used to compare the differences in mean values and proportions, respectively. The a priori level of *P*-value was set at *P*\<0.05. Missing data were not estimated or included in the analysis. The database, called Micromedex^®^ Solutions (Truven Health Analytics™), was also utilized to analyze DDIs between prescription and OTC drugs.

Results
=======

During the study period, 345 patients participated in this study ([Figure 1](#f1-ppa-12-1597){ref-type="fig"}). The characteristics of the survey respondents are shown in [Table 1](#t1-ppa-12-1597){ref-type="table"}. One hundred and ninety-three (55.9%) were female patients, and the mean age of total respondents was 61.4±12.3 years. The majority of respondents (91.3%) had national health insurance. The mean number of prescription medications taken by the respondents was 3.7±2.2. The most frequently diagnosed CD was HTN, followed by DM, hyperlipidemia and gastroduodenitis. The characteristics of the survey respondents listed according to the use of OTC drugs are presented in [Table 2](#t2-ppa-12-1597){ref-type="table"}. Among 224 OTC drug users, 149 (66.5%) were aged \<65 years, and 75 (33.5%) aged ≥65 years (*P*=0.012).

The prevalence and patterns of CDs according to gender and age are presented in [Table 3](#t3-ppa-12-1597){ref-type="table"}. The prevalence rate of gonarthrosis was significantly higher in women than in men (5.7% vs 0.0%; *P*=0.003). The prevalence rates of HTN (87.9% vs 77.9%; *P*=0.020), gastroduodenitis (18.9% vs 7.0%; *P*=0.001), gonarthrosis (6.8% vs 0.9%; *P*=0.003), heart failure (6.8% vs 0.5%; *P*=0.001), gastroesophageal reflux disease (4.5% vs 0.9%; *P*=0.031) and muscle tension (5.3% vs 0.5%; *P*=0.004) were significantly higher in respondents aged ≥65 years than in those aged \<65 years.

The OTC drug use patterns of the survey respondents according to gender and age are presented in [Table 4](#t4-ppa-12-1597){ref-type="table"}. The most commonly used OTC drugs were antipyretics, analgesics and anti-inflammatory drugs (43.5%), followed by antihistamines (25.8%), digestives (18.0%), antitussives and expectorants (13.6%), antacids (9.6%) and antiemetics (8.1%). The antipyretic, analgesic and anti-inflammatory drugs were used by 49.3% and 34.1% of respondents aged \<65 years and ≥65 years, respectively, and there was a significant difference between the two groups (*P*=0.006). Antihistamines and antitussives/expectorants were used by 31.5% and 17.4% of respondents aged \<65 years, and 16.7% and 7.6% of respondents aged ≥65 years, respectively. There were significant differences in drug use between the two age groups (antihistamines, *P*=0.002; antitussives and expectorants, *P*=0.010). The use of antitussives/expectorants, antacids and antiemetics was 19.1%, 13.2% and 4.6% in male patients, and 9.3%, 6.7% and 10.9% in female patients, respectively. The difference in drug use between genders was significant for all three types of drugs (antitussives and expectorants, *P*=0.009; antacids, *P*=0.044; antiemetics, *P*=0.034).

The views of the survey respondents toward OTC drug use according to gender and age are shown in [Table 5](#t5-ppa-12-1597){ref-type="table"}. The most common reason for using an OTC drug was cold (28.1%), followed by dyspepsia (22.6%) and pain (19.4%). In order to relieve pain, 28.3% of male patients and 12.4% of female patients used OTC medications, and the result showed a significant inter-group difference (*P*\<0.001). More respondents aged \<65 years (25.4%) used OTC medications to reduce pain when compared with those aged ≥65 years (9.8%) (*P*\<0.001). Approximately 83% of the survey respondents had used OTC medications less than six times within the last 30 days. Based on a 5-point Likert scale, questions "Q3," "Q4" and "Q5" had relatively higher mean values (3.9±0.9, 4.0±1.1 and 3.6±1.4, respectively) than question "Q6" (2.7±1.3). Only question "Q6" showed a significant difference in response (*P*\<0.001) between respondents aged \<65 years (2.9±1.3) and those aged ≥65 years (2.3±1.2). When a 4-point Likert scale was used to evaluate the question "Q7," the mean was 2.2±1.2. The mean values for question "Q7" between male (2.4±1.2) and female (2.0±1.2) patients were significantly different (*P*=0.006). Similarly, there was a significant difference (*P*\<0.001) in mean values for question "Q7" between respondents aged \<65 years (2.5±1.2) and those aged ≥65 years (1.8±1.1).

The DDIs between prescription and OTC medications are shown in [Table 6](#t6-ppa-12-1597){ref-type="table"}. Cilostazol and *Ginkgo biloba* together were most frequently used (10 cases) and concurrent use of them may cause increased risk of bleeding. Combined use of non-steroidal anti-inflammatory drugs and thiazide diuretics may reduce diuretic effectiveness and possibly cause nephrotoxicity. Increased risk of hypoglycemia may occur with concurrent use of antidiabetic agents and thioctic acid. Coadministration of diltiazem and clopidogrel may reduce the antiplatelet effect of clopidogrel and increase the risk of thrombotic events.

Discussion
==========

In this study, we examined OTC drug use patterns and assessed patients' perceptions about OTC drug use in Korean patients with CDs who visited a community pharmacy during September 2015. The main finding of this study was that \~92% of the survey respondents had taken ≥2 prescription medications and about 64% of them had used OTC medications for the purpose of self-treatment. The most frequently used OTC medications were antipyretics, analgesics and anti-inflammatory drugs such as acetaminophen and ibuprofen. The most common reason for using an OTC medication was to relieve cold, followed by dyspepsia and pain.

The findings revealed that about 64% (224/345) of respondents had used OTC drugs, which may be due to CDs with which the respondents had been diagnosed to some degree. Because of their CD status, patients are more likely to add supplements (eg, OTC medications) to their drug regimens in order to help improve their conditions. Gazibara et al reported that the number of CD treated was related to the number of OTC drugs used.[@b15-ppa-12-1597] In other words, patients with multiple CDs may use multiple OTC drugs. Compared with the results from other studies regarding the use of OTC medications in the UK (38.0%), Serbia (57.0%) and Northern Ireland (32.2%), the prevalence of OTC drug use in this study was higher.[@b15-ppa-12-1597]--[@b17-ppa-12-1597] However, because the studies in the UK and Serbia were conducted with patients aged ≥65 years, the prevalence of OTC medication use in this study (21.7%, 75/345) was likely to be lower than that in the two countries.

Although there was no statistically significant difference, the finding that women used more OTC medications than men was in line with the results from previous studies conducted in other countries.[@b13-ppa-12-1597],[@b15-ppa-12-1597],[@b17-ppa-12-1597] Among the 224 respondents in this study, 52.2% were women, and among the 202 OTC medication users in Serbia, 63.4% were women.[@b15-ppa-12-1597] This higher prevalence of OTC medication use among women can be, to some degree, explained by difference in pain perception (eg, menstrual pain), higher health awareness, higher utilization of health services and better knowledge on medications.[@b13-ppa-12-1597],[@b18-ppa-12-1597]

The most frequently used OTC medications among our survey respondents were antipyretics, analgesics and anti-inflammatory drugs. This finding was in agreement with those of other studies.[@b11-ppa-12-1597],[@b15-ppa-12-1597],[@b19-ppa-12-1597] These drugs are used to relieve muscle and joint pain, headache and cold symptoms, which our survey respondents answered as the reasons for using OTC medications. Interestingly, the use of these drugs were more common in respondents aged \<65 years (49.3%) than those aged ≥65 years (34.1%). It was thought that the elderly, aged ≥65 years, took prescription drugs instead of OTC drugs for relieving pain and cold symptoms because they could save money by utilizing national health insurance co-payment. According to the Korean Health Insurance Review and Assessment Service, patients aged ≥65 years pay only 1,500 won (1,100 won =1.00 USD) when the cost of prescription drugs is ≤15,000 won for the treatment of outpatients.[@b20-ppa-12-1597] It was also shown that more men (19.1%) tended to use antitussives and expectorants than women (9.3%). This result can be partially explained by a gender difference in smoking status in Korea. Kim et al reported that over five times more men than women smoked in Korea (84.0% vs 16.0%).[@b21-ppa-12-1597]

Using OTC medications is not always safe and beneficial for patients because they can be exposed to unexpected DRPs such as ADRs and DDIs. When the respondents were asked whether an OTC drug could cause adverse reactions or interact with prescription drugs, their level of awareness was lower than expected. Although it is difficult to directly compare this result with that from a study conducted with Italian drug consumers due to difference in measurement method, most Italian patients who participated in the study recognized the potential ADRs and DDIs that could result from using OTC medications.[@b22-ppa-12-1597] It was also shown that respondents aged \<65 years better recognized the potential ADRs and DDIs of OTC drugs than those aged ≥65 years. Despite the difference in age classification of patients, according to a study in Germany, participants aged ≥60 years had lower awareness of OTC drug safety than those who were younger.[@b13-ppa-12-1597] This result may be partially explained by the difference in the tendency of reading package leaflets of OTC medications. In this study, more patients aged \<65 years tended to read the package leaflets of OTC drugs than those aged ≥65 years.

Our study indicated that the level of reading package leaflets of OTC drugs was relatively low, similar to that of a previous study. Among 300 survey respondents, 46.3% reported that they read package leaflets depending on their degree of knowledge on OTC medications, while 5.7% reported to have never read them.[@b13-ppa-12-1597] However, the survey respondents did not give equal attention to all information contained in the package leaflets. Dose, indication and contraindications were the most read information; those about duration and interactions received less attention, whereas information about side effects received the least attention.[@b13-ppa-12-1597] In addition, according to a study conducted by Calamusa et al, 70.7% of survey respondents reported using the package leaflets of OTC drugs as the main source of information about OTC medications; however, only 38.1% of them reported to have completely understood the contents of the package leaflets.[@b22-ppa-12-1597] A similar result was reported in another study published in 2000.[@b23-ppa-12-1597] Furthermore, \~40% of the respondents also had difficulty in calculating the maximum daily dosage based on information from the package leaflets.[@b22-ppa-12-1597]

Consequently, it is important to help patients to more frequently utilize the information contained in package leaflets and to improve their understanding of functional health literacy by adopting plain language and including glossaries and additional explanations. Pharmacists are able to partially help in achieving these objectives. Previous studies showed that the recommendations of pharmacists most often affect the choice of OTC medications by patients.[@b17-ppa-12-1597],[@b24-ppa-12-1597],[@b25-ppa-12-1597] A nationwide survey conducted in Germany reported that pharmacies were the most common place where patients visited to obtain information about OTC medications.[@b26-ppa-12-1597] A systematic review by Raynor et al reported that patients preferred information about OTC medication tailored to their individual health conditions and illness by pharmacists to that prepared by manufacturers according to strict regulations.[@b27-ppa-12-1597] Moreover, as shown in this study, patients with CDs took OTC medications and prescription medications, which may increase the risk of ADRs, DDIs, and drug--disease interactions. For example, combined use of *G. biloba* and cilostazol, most frequently used in this study, did not strengthen an antiplatelet effect when compared with using individual agents, but *G. biloba* tended to prolong bleeding time related to cilostazol.[@b28-ppa-12-1597] These DRPs and CDs can be better managed through medication therapy management (MTM) services provided by pharmacists.

Limitations
-----------

This study has some limitations, which must be considered when interpreting the data. The first limitation of this study is the representativeness of the survey respondents. Most of the respondents were probably residents of a small city located in the southern region of South Korea. Therefore, it is somewhat difficult to generalize the results from this study to other regions (eg, metropolitan area) of South Korea. In future studies, similar surveys will have to be carried out in other regions, before the overall results can be assessed and utilized as basic data in developing total patient care programs, such as MTM services, in Korean community pharmacies. Second, we did not consider patients' non-demographic and lifestyle factors, which could affect their OTC medication use as demonstrated in previous studies.[@b29-ppa-12-1597],[@b30-ppa-12-1597] Third, herbal medicinal preparations and functional foods are widely used in South Korea; however, we did not consider patients' use of these products, which may possibly cause various interactions with prescription/OTC medications and diseases. Finally, the results from this study may have overestimated the perspectives of the rest of the population because we excluded patients who were illiterate or had not continuously taken prescription medications for at least 3 months.

Conclusion
==========

In Korea, OTC medications can easily be obtained at pharmacies for the purpose of self-treatment. Approximately 64% of Korean survey respondents reported that they had used OTC drugs. The most commonly used OTC medications were antipyretics, analgesics and anti-inflammatory drugs, and these drugs were more commonly used by respondents aged \<65 years than those aged ≥65 years. The awareness level of Korean consumers on DRPs such as ADRs and DDIs resulting from the use of OTC medications was relatively low. Although package leaflets are the main source of information about OTC medications, Korean consumers' level of reading these package leaflets was also relatively low. Based on these results, we believe this study can be pivotal in identifying starting points for interventions by health care professionals such as doctors, pharmacists and other health care workers. In particular, pharmacists should inform their consumers of possible DRPs from OTC medications when counseling them. However, information about OTC medications should be tailored to consumers' needs, with consideration of his or her circumstance.
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###### 

Participant demographic and clinical characteristics

  -------------------------------------------------------------------------------------
  Characteristics                                                       Total, n (%)\
                                                                        (n=345)
  --------------------------------------------------------------------- ---------------
  Gender                                                                

   Male                                                                 152 (44.1)

   Female                                                               193 (55.9)

  Age (years), mean ± SD                                                61.4±12.3

   \<45                                                                 21 (6.1)

   45--54                                                               95 (27.5)

   55--64                                                               97 (28.1)

   65--74                                                               74 (21.4)

   ≥75                                                                  58 (16.8)

  Types of insurance                                                    

   National health insurance                                            315 (91.3)

   National medical aid                                                 29 (8.4)

   Industrial accident compensation insurance                           0 (0.0)

   Car insurance                                                        0 (0.0)

   Others                                                               1 (0.3)

  Number of prescription medications taken by participants, mean ± SD   3.7±2.2

   ≤1                                                                   27 (7.8)

   2--4                                                                 228 (66.1)

   5--9                                                                 79 (22.9)

   ≥10                                                                  11 (3.2)

  Ten most frequently diagnosed chronic diseases in participants        

   Hypertension                                                         282 (81.7)

   Diabetes mellitus                                                    104 (30.1)

   Hyperlipidemia                                                       97 (28.1)

   Gastroduodenitis                                                     40 (11.6)

   Gonarthrosis                                                         11 (3.2)

   Menopausal disorders                                                 11 (3.2)

   Heart failure                                                        10 (2.9)

   Gastroesophageal reflux disease                                      8 (2.3)

   Dyspepsia                                                            8 (2.3)

   Muscle tension                                                       8 (2.3)
  -------------------------------------------------------------------------------------

###### 

Participant demographic and clinical characteristics according to the use of OTC medications

  Characteristics                                            OTC medication user, n (%) (n=224)   OTC medication non-user, n (%) (n=121)   *P*-value[a](#tfn1-ppa-12-1597){ref-type="table-fn"}
  ---------------------------------------------------------- ------------------------------------ ---------------------------------------- ------------------------------------------------------
  Gender                                                                                                                                   
   Male                                                      107 (47.8)                           45 (37.2)                                0.058
   Female                                                    117 (52.2)                           76 (62.8)                                
  Age (years)                                                                                                                              
   \<65                                                      149 (66.5)                           64 (52.9)                                0.012
   ≥65                                                       75 (33.5)                            57 (47.1)                                
  Number of prescription medications taken by participants                                                                                 
   ≤1                                                        19 (8.5)                             8 (6.5)                                  0.445
   2--4                                                      146 (65.2)                           82 (67.8)                                
   5--9                                                      54 (24.1)                            25 (20.7)                                
   ≥10                                                       5 (2.2)                              6 (5.0)                                  
  Chronic disease                                                                                                                          
   Hypertension                                              183 (81.7)                           99 (81.8)                                0.978
   Diabetes mellitus                                         62 (27.7)                            42 (34.7)                                0.174
   Hyperlipidemia                                            60 (26.8)                            37 (30.6)                                0.455
   Gastroduodenitis                                          23 (10.3)                            17 (14.0)                                0.295
   Gonarthrosis                                              6 (2.7)                              5 (4.1)                                  0.463
   Menopausal disorders                                      8 (3.6)                              3 (2.5)                                  0.582
   Heart failure                                             3 (1.3)                              7 (5.8)                                  0.019
   Gastroesophageal reflux disease                           4 (1.8)                              4 (3.3)                                  0.371
   Dyspepsia                                                 2 (0.9)                              6 (5.0)                                  0.017
   Muscle tension                                            4 (1.8)                              4 (3.3)                                  0.371

**Note:**

Chi-squared test or Fisher's exact test.

**Abbreviation:** OTC, over-the-counter.

###### 

Prevalence and patterns of chronic diseases according to gender and age

  ---------------------------------------------------------------------------------------------------------------------
  Chronic diseases                  Total, n (%)\   Gender       Age                                            
                                    (n=345)                                                                     
  --------------------------------- --------------- ------------ ------------ ------- ------------ ------------ -------
  Hypertension                      282 (81.7)      121 (79.6)   161 (83.4)   0.363   166 (77.9)   116 (87.9)   0.020

  Diabetes mellitus                 104 (30.1)      47 (30.9)    57 (29.5)    0.780   61 (28.6)    43 (32.6)    0.439

  Hyperlipidemia                    97 (28.1)       37 (24.3)    60 (31.1)    0.166   58 (27.2)    39 (29.5)    0.642

  Gastroduodenitis                  40 (11.6)       14 (9.2)     26 (13.5)    0.220   15 (7.0)     25 (18.9)    0.001

  Gonarthrosis                      11 (3.2)        0 (0.0)      11 (5.7)     0.003   2 (0.9)      9 (6.8)      0.003

  Menopausal disorders              11 (3.2)        --           11 (5.7)     --      10 (4.7)     1 (0.8)      0.043

  Heart failure                     10 (2.9)        4 (2.6)      6 (3.1)      0.793   1 (0.5)      9 (6.8)      0.001

  Gastroesophageal reflux disease   8 (2.3)         4 (2.6)      4 (2.1)      0.732   2 (0.9)      6 (4.5)      0.031

  Dyspepsia                         8 (2.3)         3 (2.0)      5 (2.6)      0.706   3 (1.4)      5 (3.8)      0.154

  Muscle tension                    8 (2.3)         4 (2.6)      4 (2.1)      0.732   1 (0.5)      7 (5.3)      0.004
  ---------------------------------------------------------------------------------------------------------------------

**Note:**

Chi-squared test or Fisher's exact test.

###### 

Participants' OTC medication use patterns according to gender and age

  ---------------------------------------------------------------------------------------------------------------------------------------
  OTC medication class                                   Total, n (%)\   Gender      Age                                          
                                                         (n=345)                                                                  
  ------------------------------------------------------ --------------- ----------- ----------- ------- ------------ ----------- -------
  Antipyretics, analgesics and anti-inflammatory drugs   150 (43.5)      66 (43.4)   84 (43.5)   0.985   105 (49.3)   45 (34.1)   0.006

  Antihistamines                                         89 (25.8)       45 (29.6)   44 (22.8)   0.151   67 (31.5)    22 (16.7)   0.002

  Digestives                                             62 (18.0)       31 (20.4)   31 (16.1)   0.298   40 (18.8)    22 (16.7)   0.619

  Antitussives and expectorants                          47 (13.6)       29 (19.1)   18 (9.3)    0.009   37 (17.4)    10 (7.6)    0.010

  Antacids                                               33 (9.6)        20 (13.2)   13 (6.7)    0.044   25 (11.7)    8 (6.1)     0.081

  Antiemetics                                            28 (8.1)        7 (4.6)     21 (10.9)   0.034   17 (8.0)     11 (8.3)    0.907

  Multivitamins                                          26 (7.5)        11 (7.2)    15 (7.8)    0.852   13 (6.1)     13 (9.8)    0.200

  Drugs for intestinal disorders                         17 (4.9)        8 (5.3)     9 (4.7)     0.798   14 (6.6)     3 (2.3)     0.079

  Antispasmodics                                         17 (4.9)        8 (5.3)     9 (4.7)     0.798   14 (6.6)     3 (2.3)     0.079

  Drugs for peptic ulcer                                 12 (3.5)        6 (3.9)     6 (3.1)     0.673   8 (3.8)      4 (3.0)     1.000

  Laxatives and enemas                                   7 (2.0)         2 (1.3)     5 (2.6)     0.472   6 (2.8)      1 (0.8)     0.258

  Skeletal muscle relaxants                              6 (1.7)         5 (3.3)     1 (0.5)     0.091   5 (2.3)      1 (0.8)     0.413

  Contraceptives                                         4 (1.2)         --          4 (2.1)     --      4 (1.9)      --          --
  ---------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Chi-squared test or Fisher's exact test.

**Abbreviation:** OTC, over-the-counter.

###### 

Participants' perspectives toward OTC medication use according to gender and age

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                          Total, n (%)\   Gender       Age                                             
                                                                                                                                                                          (n=345)                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------ ------------ --------- ------------ ----------- ---------
  Q1. What is your reason for using an OTC drug?                                                                                                                                                                                                       

  Pain                                                                                                                                                                    67 (19.4)       43 (28.3)    24 (12.4)    \<0.001   54 (25.4)    13 (9.8)    \<0.001

  Cold                                                                                                                                                                    97 (28.1)       40 (26.3)    57 (29.5)    0.509     67 (31.5)    30 (22.7)   0.080

  Dyspepsia                                                                                                                                                               78 (22.6)       37 (24.3)    41 (21.2)    0.495     49 (23.0)    29 (22.0)   0.823

  Heartburn                                                                                                                                                               34 (9.9)        19 (12.5)    15 (7.8)     0.144     23 (10.8)    11 (8.3)    0.455

  Fatigue                                                                                                                                                                 28 (8.1)        14 (9.2)     14 (7.3)     0.509     19 (8.9)     9 (6.8)     0.487

  Diarrhea                                                                                                                                                                6 (1.7)         1 (0.7)      5 (2.6)      0.235     5 (2.3)      1 (0.8)     0.413

  Constipation                                                                                                                                                            17 (4.9)        8 (5.3)      9 (4.7)      0.798     14 (6.6)     3 (2.3)     0.079

  Others                                                                                                                                                                  48 (13.9)       20 (13.2)    28 (14.5)    0.719     23 (10.8)    25 (18.9)   0.034

  Q2. How often had you used an OTC drug within the last 30 days?                                                                                                                                                                                      

  \<6                                                                                                                                                                     285 (82.6)      129 (84.9)   156 (80.8)   0.326     190 (89.2)   95 (72.0)   \<0.001

  ≥6                                                                                                                                                                      60 (17.4)       23 (15.1)    37 (19.2)              23 (10.8)    37 (28.0)   

  Q3. Do you think that an OTC drug is effective?[b](#tfn7-ppa-12-1597){ref-type="table-fn"}                                                                                                                                                           

  Mean ± SD                                                                                                                                                               3.9±0.9         4.0±1.0      3.9±0.9      0.573     3.9±0.9      3.9±1.0     0.754

  Q4. Do you think that pharmacists' medication counseling is necessary when purchasing an OTC drug?[b](#tfn7-ppa-12-1597){ref-type="table-fn"}                                                                                                        

  Mean ± SD                                                                                                                                                               4.0±1.1         4.0±1.2      4.0±1.0      0.978     4.0±1.1      4.0±1.0     0.840

  Q5. Do you give pharmacists information on drugs which you currently take when purchasing an OT C drug?[b](#tfn7-ppa-12-1597){ref-type="table-fn"}                                                                                                   

  Mean ± SD                                                                                                                                                               3.6±1.4         3.6±1.4      3.6±1.4      0.879     3.6±1.4      3.7±1.3     0.620

  Q6. Do you know that an OTC drug can cause adverse reactions or interact with prescription drugs which you currently take?[b](#tfn7-ppa-12-1597){ref-type="table-fn"}                                                                                

  Mean ± SD                                                                                                                                                               2.7±1.3         2.7±1.4      2.7±1.3      0.524     2.9±1.3      2.3±1.2     \<0.001

  Q7. Do you read the package leaflet of an OTC drug when using it?[c](#tfn8-ppa-12-1597){ref-type="table-fn"}                                                                                                                                         

  Mean ± SD                                                                                                                                                               2.2±1.2         2.4±1.2      2.0±1.2      0.006     2.5±1.2      1.8±1.1     \<0.001
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Chi-squared test, Fisher's exact test or independent *t*-test.

Rating scale: 5= strongly agree, 4= agree, 3= neutral, 2= disagree and 1= strongly disagree.

Rating scale: 4= strongly agree, 3= agree, 2= disagree and 1= strongly disagree.

**Abbreviation:** OTC, over-the-counter.

###### 

Drug--drug interactions between drugs that participants had taken

  Drugs           Interaction drug                          Frequency of use   Severity[a](#tfn10-ppa-12-1597){ref-type="table-fn"}   Quality of evidence[b](#tfn11-ppa-12-1597){ref-type="table-fn"}   Summary
  --------------- ----------------------------------------- ------------------ ------------------------------------------------------ ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Aspirin         Thiazide                                  6                  Major                                                  Good                                                              Reduced diuretic effectiveness and possible nephrotoxicity
                  Atenolol, bisoprolol, carvedilol          6                  Moderate                                               Good                                                              Decreased antihypertensive effect
                  Meloxicam                                 2                  Major                                                  Fair                                                              Increased risk of bleeding
                  Ranitidine                                6                  Minor                                                  Excellent                                                         Decreased plasma levels of aspirin and its antiplatelet effect
                  Al(OH)~2~, Mg(OH)~2~, MgO                 5                  Moderate                                               Fair                                                              Decreased effectiveness of aspirin
                                                                                                                                                                                                        
  Atenolol        Diltiazem                                 1                  Major                                                  Good                                                              Increased risk of hypotension, bradycardia, AV conduction disturbances
                  Glimepiride, metformin                    3                  Moderate                                               Good                                                              Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia
                  Al(OH)~2~, Mg(OH)~2~, CaCO~3~             4                  Minor                                                  Good                                                              Decreased effectiveness of atenolol
                                                                                                                                                                                                        
  Belladonna      Chlorpheniramine                          1                  Minor                                                  Fair                                                              Excessive anticholinergic activity
                                                                                                                                                                                                        
  Caffeine        Alprazolam, lorazepam                     2                  Minor                                                  Good                                                              Decreased sedative and anxiolytic effects of alprazolam and lorazepam
                  Estradiol valerate, medroxyprogesterone   2                  Moderate                                               Good                                                              Enhanced central nervous system stimulation
                                                                                                                                                                                                        
  Carvedilol      Metformin, sitagliptin                    2                  Moderate                                               Good                                                              Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia
                                                                                                                                                                                                        
  Cilostazol      *Ginkgo biloba*                           10                 Major                                                  Good                                                              Increased risk of bleeding
                                                                                                                                                                                                        
  Diltiazem       Clopidogrel                               2                  Major                                                  Excellent                                                         Decreased antiplatelet effect and increased risk of thrombotic events
                  Ranitidine                                1                  Minor                                                  Good                                                              Increased diltiazem concentrations and possible cardiovascular toxicity
                                                                                                                                                                                                        
  Fluconazole     Atorvastatin                              1                  Major                                                  Fair                                                              Increased risk of myopathy or rhabdomyolysis
                  Tamsulosin                                1                  Moderate                                               Fair                                                              Increased exposure of tamsulosin
                  Tramadol                                  1                  Major                                                  Fair                                                              Increased tramadol exposure and risk of toxicity
                                                                                                                                                                                                        
  *G. biloba*     Thiazide                                  3                  Moderate                                               Good                                                              Increased blood pressure
                                                                                                                                                                                                        
  Glimepiride     Carvedilol, nebivolol                     2                  Moderate                                               Good                                                              Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia
                  Sitagliptin                               8                  Moderate                                               Fair                                                              Increased risk of hypoglycemia
                  Ranitidine                                1                  Moderate                                               Fair                                                              Increased blood glucose-lowering effect and increased risk of hypoglycemia
                  Thioctic acid                             4                  Major                                                  Fair                                                              Increased risk of hypoglycemia
                                                                                                                                                                                                        
  Meloxicam       Angiotensin II receptor blockers          3                  Moderate                                               Excellent                                                         Renal dysfunction or decreased antihypertensive efficacy
                  Thiazide                                  3                  Major                                                  Good                                                              Reduced diuretic effectiveness and possible nephrotoxicity
                  Carvedilol                                1                  Moderate                                               Good                                                              Decreased antihypertensive effect
                                                                                                                                                                                                        
  Prednisolone    Thiazide                                  1                  Moderate                                               Fair                                                              Hypokalemia
                                                                                                                                                                                                        
  Rosuvastatin    Al(OH)~2~, Mg(OH)~2~                      2                  Moderate                                               Fair                                                              Decreased rosuvastatin effectiveness
                                                                                                                                                                                                        
  Thiazide        Ibuprofen                                 1                  Major                                                  Good                                                              Reduced diuretic effectiveness and possible nephrotoxicity
                  CaCO~3~                                   1                  Moderate                                               Fair                                                              Increased risk of hypercalcemia
                                                                                                                                                                                                        
  Thioctic acid   Metformin, sitagliptin                    4                  Major                                                  Fair                                                              Increased risk of hypoglycemia
                                                                                                                                                                                                        
  Tramadol        Amitriptyline                             1                  Major                                                  Fair                                                              Increased risk of seizure, serotonin syndrome, opioid toxicity and increased levels of tramadol

**Notes:**

Contraindicated -- the drugs are contraindicated for concurrent use; major -- the interaction may be life-threatening and/or need medical intervention to minimize or prevent serious adverse effects; moderate -- the interaction may exacerbate the patient's condition and/or need an alternative therapy; minor -- the interaction may cause an increase in the frequency or severity of side effects but would not need a major alternative therapy.

Excellent -- the existence of the interaction has clearly been established through controlled studies; good -- the existence of the interaction is strongly suggested through documentation, but well-controlled studies are rare; fair -- available documentation is poor, but pharmacologic concerns lead clinicians to suspect the existence of the interaction or documentation regarding pharmacologically similar drug is good.

**Abbreviation:** AV, atrioventricular.

[^1]: These authors contributed equally to this work
